Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakayama Yoichi, Nagata Wataru, Takeuchi Yoichi, Fukui Sho, Fujita Yuya, Hosokawa Yohei, Ueno Masanobu, Ono Kumiko, Sumitomo Shuji, Tabuchi Yuya, Nakanishi Yuichiro, Saito Shuntaro, Ikeuchi Hiroko, Kawamori Kazutaka, Sofue Hideaki, Doi Goro, Minami Runa, Hirota Tomoya, Minegishi Kaoru, Maeshima Keisuke, Motoyama Ryo, Nakamura Shohei, Suzuki Shotaro, Nishioka Norihiro, Wada Takuma Tsuzuki, Onishi Akira, Nishimura Kenichi, Watanabe Ryu, Yanai Ryo, Kida Takashi, Nishiwaki Hiroki, Yajima Nobuyuki, Kaneko Yuko, Tanaka Eiichi, Kawahito Yutaka, Harigai Masayoshi
Аннотация
METHODS: We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses.
RESULTS: Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naïve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (csDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients.
CONCLUSIONS: This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.